Summit Global Investments Collegium Pharmaceutical, Inc Transaction History

Summit Global Investments

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 04, 2023	SELL	$23.0 - $29.88 $41,768 - $54,262	-1,816 Reduced 1.85%	96,485 $2.32 Million
Q4 2022 Jan 31, 2023	BUY	$16.14 - $23.55 $5,923 - $8,642	367 Added 0.37%	98,301 $2.28 Million
Q3 2022 Nov 14, 2022	SELL	$15.46 - $20.1 $195,909 - $254,707	-12,672 Reduced 11.46%	97,934 $1.57 Million
Q2 2022 Aug 23, 2022	BUY	$14.22 - $20.88 $800,671 - $1.18 Million	56,306 Added 103.69%	110,606 $1.96 Million
Q1 2022 Apr 29, 2022	SELL	$17.2 - $22.5 $443,760 - $580,500	-25,800 Reduced 32.21%	54,300 $1.11 Million
Q4 2021 Feb 14, 2022	BUY	$17.5 - $21.35 $194,250 - $236,985	11,100 Added 16.09%	80,100 $1.5 Million
Q3 2021 Nov 08, 2021	BUY	$17.75 - $25.39 $715,325 - $1.02 Million	40,300 Added 140.42%	69,000 $1.36 Million
Q2 2021 Jan 28, 2022	BUY	$21.74 - $25.28 $623,938 - $725,536	28,700 New	28,700 $678,000

254

36.9M

100K

21.1K

Ticker COLL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 34,126,200
Market Cap $1.12B
Description
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...

Get notified when there are updates to the investment portfolio of Summit Global Investments, based on Form 13F filings with the SEC.

Stay updated on Summit Global Investments with notifications on news.